CST3 and cancer: Similarly, cystatin C was found to be aberrantly high in a study conducted by Jones M. et al. on cancer patients [7], and the authors concluded that cystatin C could bias renal function evaluation in this patient’s typology for which a parameter to be strictly monitored in relation to the treatment is strongly needed.